P300 was unaffected by luvadaxistat
We also tested P300 ERP. The LS mean change ± SEM from baseline in P300 target amplitude at day 8 was −2.019 ± 1.68 for subjects treated with luvadaxistat 50 mg compared with 0.608 ± 1.68 for those treated with placebo and was 1.102 ± 1.77 for subjects treated with luvadaxistat 500 mg compared with 2.595 ± 1.86 for those treated with placebo (Fig. 